ARTICLE | Clinical News
CMB305: Phase Ib data
February 15, 2016 8:00 AM UTC
Top-line data from an open-label, dose-escalation, U.S. Phase Ib trial in patients with locally advanced, relapsed or metastatic cancers expressing NY-ESO-1 showed that CMB305 was safe with no dose-li...